|
| 首个新一代靶向降脂药PSCK9抑制药阿里罗单抗概述 |
| First in a New Class of Cholesterol lowering Drugs PCSK9 Inhibitor: Alirocumab |
| |
| DOI： |
| 中文关键词: 阿里罗单抗 前蛋白转化酶枯草溶菌素9抑制药 单克隆抗体 低密度脂蛋白胆固醇 |
| 英文关键词:Alirocumab PCSK9 inhibitor A human monoclonal antibody LDL-C |
| 基金项目: |
|
| 摘要点击次数: 1545 |
| 全文下载次数: 1140 |
| 中文摘要: |
| 摘 要全面介绍首个新一代靶向降脂药——前蛋白转化酶枯草溶菌素9（PSCK9）抑制药阿里罗单抗，其通过与抗肝细胞表面的低密度脂蛋白受体(LDLR)靶向结合，降低低密度脂蛋白胆固醇（LDL-C），用于治疗原发性高脂血症，为膳食控制和最大耐受量的他汀类药物的辅助治疗，对于患杂合子家族性高胆固醇血症(HeFH)和或合并动脉粥样硬化性心血管病，需要进一步降低LDL C水平的成年患者提供了新的选择。 |
| 英文摘要: |
| ABSTRACTTo introduction description of the first in a new class of cholesterol-lowering drugs PCSK9 inhibitor alirocumab，it specifically binds proprotein convertase subtilisin/kexin type 9 (PCSK9)-a down regulator of liver low density lipoprotein (LDL)-receptors thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. It has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C.This article summarizes the milestones in the development of alirocumab leading to this first approval. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
